ATE249046T1 - Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können - Google Patents

Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können

Info

Publication number
ATE249046T1
ATE249046T1 AT97923067T AT97923067T ATE249046T1 AT E249046 T1 ATE249046 T1 AT E249046T1 AT 97923067 T AT97923067 T AT 97923067T AT 97923067 T AT97923067 T AT 97923067T AT E249046 T1 ATE249046 T1 AT E249046T1
Authority
AT
Austria
Prior art keywords
chaperones
prpsc
prpc
isoforms
differentiate
Prior art date
Application number
AT97923067T
Other languages
English (en)
Inventor
Ernst-Ludwig Winnacker
Stefan Weiss
Frank Edenhofer
Roman Rieger
Original Assignee
Winnacker Ernst Ludwig Prof
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winnacker Ernst Ludwig Prof filed Critical Winnacker Ernst Ludwig Prof
Application granted granted Critical
Publication of ATE249046T1 publication Critical patent/ATE249046T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
AT97923067T 1996-05-14 1997-05-13 Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können ATE249046T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96107677 1996-05-14
PCT/EP1997/002444 WO1997043649A1 (en) 1996-05-14 1997-05-13 CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿

Publications (1)

Publication Number Publication Date
ATE249046T1 true ATE249046T1 (de) 2003-09-15

Family

ID=8222782

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923067T ATE249046T1 (de) 1996-05-14 1997-05-13 Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können

Country Status (6)

Country Link
US (2) US6451541B1 (de)
EP (1) EP0914614B1 (de)
JP (1) JP3745380B2 (de)
AT (1) ATE249046T1 (de)
DE (1) DE69724619T2 (de)
WO (1) WO1997043649A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186662A3 (de) * 1996-05-29 2003-01-15 McGILL UNIVERSITY Prionbindendes Proteine und deren Verwendungen
US6620629B1 (en) 1997-02-21 2003-09-16 The Regents Of The University Of California Method for detecting prions
US6617119B2 (en) 1997-02-21 2003-09-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
US6720355B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Sodium dodecyl sulfate compositions for inactivating prions
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US6719988B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Antiseptic compositions for inactivating prions
AU764888B2 (en) * 1997-02-21 2003-09-04 Regents Of The University Of California, The Assay for disease related conformation of a protein
US6214565B1 (en) 1998-10-09 2001-04-10 The Regents Of The University Of California Assay for disease related conformation of a protein and isolating same
US5977324A (en) * 1998-02-20 1999-11-02 The Regents Of The University Of California Process for concentrating protein with disease-related conformation
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
EP1216258A1 (de) * 1999-09-28 2002-06-26 Universität Zürich Faktoren mit prionen bindender aktivität im serum und plasma sowie mittel zur bestimmung von übertragbaren spongiformen encephalopathien
WO2001023894A1 (de) * 1999-09-28 2001-04-05 Evotec Oai Ag Quantitative analyse und typisierung subzellulärer partikel
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US7166471B2 (en) 2001-05-31 2007-01-23 Arete Associates Misfolded protein sensor method in body fluids
JP2005510460A (ja) * 2001-08-10 2005-04-21 メディカル リサーチ カウンシル 分子
WO2003085086A2 (en) * 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
NZ572892A (en) * 2002-12-03 2010-03-26 Univ North Carolina State Prion protein ligands with the sequence YVHEA
CA2521438C (en) * 2003-04-04 2014-03-25 Steven J. Burton Prion protein binding materials and methods of use
JP5162250B2 (ja) * 2005-01-13 2013-03-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬を使用するｅｌｉｓａアッセイ
ATE528649T1 (de) * 2005-02-15 2011-10-15 Adlyfe Inc Verfahren zum nachweis falsch gefalteter proteine und prionen
WO2007089591A2 (en) * 2006-01-27 2007-08-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for high throughput screening of pharmacological chaperones
MX2009001079A (es) * 2006-07-28 2009-02-10 Adlyfe Inc Sondas de peptido para diagnosis y terapeutica.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993023432A1 (en) * 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
ES2201137T3 (es) * 1994-12-21 2004-03-16 Yeda Research And Development Co. Ltd. Analogos del peptido p277 y composiciones farmaceuticas que los comprenden para el tratamiento o diagnostico de la diabetes.
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
EP0914614A1 (de) 1999-05-12
US6451541B1 (en) 2002-09-17
DE69724619D1 (de) 2003-10-09
JP2000516572A (ja) 2000-12-12
US20050227287A1 (en) 2005-10-13
DE69724619T2 (de) 2004-07-01
JP3745380B2 (ja) 2006-02-15
WO1997043649A1 (en) 1997-11-20
EP0914614B1 (de) 2003-09-03

Similar Documents

Publication Publication Date Title
ATE249046T1 (de) Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
DE60217090D1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
SG147275A1 (en) Prevention and treatment of amyloidogenic disease
NO961326D0 (no) Inhibitorer av
NO20100264L (no) Forhindring og behandling av amyloidogen sykdom
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
CY1117925T1 (el) Μεθοδος αγωγης και βιοπροσδιορισμος που σχετιζεται με παραγοντα αναστολης της μεταναστευσης των μακροφαγων (mif) ως προερχομενο απο την καρδια μυοκαρδιακο κατασταλτικο παραγοντα
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
MA27311A1 (fr) Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE59608213D1 (de) Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
ATE198278T1 (de) Verwendung von sulodexid und von arzneimitteln, die dieses enthalten, zur behandlung der diabetischen nephropathie
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
Rich et al. Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
ATE198990T1 (de) Konjugat zur behandlung von entzündlichen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties